Publication Name	World Journal of Meta-Analysis
Manuscript ID	60756
Country	India

Received	2020-11-12 07:16
Peer-Review Started	2020-11-12 07:16
To Make the First Decision
Return for Revision	2021-02-12 14:30
Revised	2021-02-16 12:08
Second Decision	2021-02-24 07:16
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2021-02-24 21:11
Articles in Press	2021-02-24 21:11
Publication Fee Transferred
Edit the Manuscript by Language Editor	2021-02-26 05:28
Typeset the Manuscript	2021-03-01 02:36
Publish the Manuscript Online	2021-03-02 12:30

ISSN	2308-3840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Infectious Diseases
Manuscript Type	Meta-Analysis
Article Title	Efficacy and safety outcomes with remdesivir in COVID-19 patients: A meta-analysis
Manuscript Source	Invited Manuscript
All Author List	Tejas Kamleshbhai Patel, Parvati B Patel, Manish Barvaliya, Vijayalaxmi and Hira Lal Bhalla
Funding Agency and Grant Number
Corresponding Author	Tejas Kamleshbhai Patel, MD, Associate Professor, Department of Pharmacology, All India Institute of Medical Sciences, Gorakhpur, Kunraghat, Gorakhpur 273008, Uttar Pradesh, India. dr.tkp2006@yahoo.co.in
Key Words	COVID-19; SARS-CoV-2; Antiviral; Pneumonia; Remdesivir; Meta-analysis; Systematic review
Core Tip	Remdesivir is an antiviral drug having in vitro and in vivo activity against severe acute respiratory syndrome coronavirus 2. United States Food and Drug Administration has granted emergency use authorization for its use in all hospitalized patients. The findings of this meta-analysis suggest remdesivir can enhance clinical recovery without having significant benefits on mortality outcomes. Due to lack of any major safety concerns its use is still recommended in the absence of effective antiviral drugs against coronavirus disease 2019.
Publish Date	2021-03-02 12:30
Citation	Patel TK, Patel PB, Barvaliya M, Vijayalaxmi, Bhalla HL. Efficacy and safety outcomes with remdesivir in COVID-19 patients: A meta-analysis. World J Meta-Anal 2021; 9(1): 74-87
URL	https://www.wjgnet.com/2308-3840/full/v9/i1/74.htm
DOI	https://dx.doi.org/10.13105/wjma.v9.i1.74

Full Article (PDF)	WJMA-9-74.pdf
Full Article (Word)	WJMA-9-74.docx
Manuscript File	60756-Review-FilipodiaCL.docx
Answering Reviewers	60756-Answering reviewers.pdf
Audio Core Tip	60756-Audio core tip.m4a
Biostatistics Review Certificate	60756-Biostatistics statement.pdf
Conflict-of-Interest Disclosure Form	60756-Conflict-of-interest statement.pdf
Copyright License Agreement	60756-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	60756-Language certificate.pdf
Peer-review Report	60756-Peer-review(s).pdf
Scientific Misconduct Check	60756-Scientific misconduct check.pdf
Scientific Editor Work List	60756-Scientific editor work list.pdf